leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals to present at Proactive’s One2One virtual investor conference, December 8th

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) CEO Christopher Moreau tells Proactive he will be one of three emerging companies that will present at Proactive’s One2One virtual investor conference on Tuesday, December 8, at 1:30PM.

Moreau offered investors a highlight on what he's expected to speak on next week. To register, please click here: https://www.proactiveinvestors.com/register/event_details/301

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.27 CAD

CSE:AGN
Market: CSE
Market Cap: $37.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceuticals looks to highly regarded UK company to conduct...

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive with news the company has chosen renowned contract research organization Hammersmith Medicines Research located in the UK to conduct their Phase 1 stroke program study using...

2 days, 23 hours ago

2 min read